Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Faron Pharmaceuticals Oy    FARN   FI4000153309

FARON PHARMACEUTICALS OY (FARN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
802.5(c) 802.5(c) 805(c) 805(c) 840(c) Last
696 4 780 182 2 094 128 237 Volume
-2.13% 0.00% +0.31% 0.00% +4.35% Change
More quotes
Financials ( GBP)
Sales 2017 0,18 M
EBIT 2017 -13,4 M
Net income 2017 -12,9 M
Finance 2017 11,3 M
Yield 2017 -
Sales 2018 1,90 M
EBIT 2018 -13,0 M
Net income 2018 -13,8 M
Debt 2018 2,68 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1 249x
EV / Sales2018 125x
Capitalization 234 M
More Financials
Company
Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development.The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage.It operates through the Traumakine and Clevegen brands for acute respiratory... 
More about the company
Latest news on FARON PHARMACEUTICALS OY
02/06FARON PHARMACEUTICALS OY : establishes second Traumakine manufacturing site as i..
AQ
01/29FARON PHARMACEUTICALS OY : FDA grants Fast Track Designation to Faron for Trauma..
AQ
01/24FDA has approved Faron's Traumakine® IND
GL
2017FARON PHARMACEUTICALS OY : Study update: Traumakine® Phase II/III INFORAAA trial..
AQ
2017FARON PHARMACEUTICALS OY : Recruitment completed in Traumakine INTEREST Trial
GL
2017BIOCENTURY - MANAGEMENT TRACKS : Athenex, Biogen
AQ
2017FARON PHARMACEUTICALS OY : Appointment of Chief Commercial Officer
AQ
2017FARON PHARMACEUTICALS OY : Appointment of Chief Commercial Officer
GL
2017FARON PHARMACEUTICALS OY : Results of the Placing and Subscription and Issue of ..
AQ
2017FARON PHARMACEUTICALS OY : Director's Dealing
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/16Faron Pharmaceuticals Oy : Proposed Placing to raise up to £15m  
01/29Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Trau.. 
01/24Faron Pharmaceuticals Oy : FDA approval of Faron's Traumakine® IND  
2017Faron Pharmaceuticals Oy: Study update: Traumakine® Phase II/III INFORAAA tri.. 
2017Faron Pharmaceuticals Oy: Recruitment completed in Traumakine INTEREST Trial .. 
More tweets
Qtime:68
Chart FARON PHARMACEUTICALS OY
Duration : Period :
Faron Pharmaceuticals Oy Technical Analysis Chart | FARN | FI4000153309 | 4-Traders
Technical analysis trends FARON PHARMACEUTICALS OY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,20  GBP
Spread / Average Target 1,8%
Managers
NameTitle
Markku Tapani Jalkanen Chief Executive Officer & Executive Director
Frank Murdoch Armstrong Non-Executive Chairman
Mikael Maksimow Vice President-Operations
Yrjö Erik Kristian Wichmann Chief Financial Officer & Executive Director
Matti Karvonen Chief Medical Officer & VP-Drug Development
Sector and Competitors
1st jan.Capitalization (M$)
FARON PHARMACEUTICALS OY0.63%332
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055